Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...
A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell ...
RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...
Utility of Tumor-Informed Circulating Tumor DNA for Monitoring Treatment Response in Nonmetastatic, Locally Advanced Penile and Primary Urethral Cancers Authors retain all rights in any data ...
Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.
Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...
"KEYTRUDA monotherapy given in the adjuvant setting remains an important treatment choice for patients with renal cell carcinoma at an increased risk of recurrence following surgery and is the only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback